Clinical Trials Browser

Phase 1/2 × Recruiting × elotuzumab × Clear all

NCT06518551 2025-12-11

Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

NCT06785415 2025-09-30

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma